SCHEMBL17236928

SCHEMBL17236928

COc1cc(C=Cc2ccc(NC=CC(=O)c3cc(OC)c(OC)c(OC)c3)cc2)cc(OC)c1OC

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.75
▸ GAA P10253 1/20 0.75
▸ MEN1 O00255 2/20 0.72
▸ KMT2A Q03164 2/20 0.72
▸ LMNA P02545 1/20 0.72
▸ GLA P06280 1/20 0.72
▸ HPGD P15428 1/20 0.72
▸ ABCG2 Q9UNQ0 2/20 0.67
▸ TNFRSF1A P19438 3/20 0.59
▸ TUBB4A P04350 3/20 0.58
▸ TUBB P07437 3/20 0.58
▸ TUBA3C P0DPH7 3/20 0.58
▸ TUBA1B P68363 3/20 0.58
▸ TUBA4A P68366 3/20 0.58
▸ TUBB4B P68371 3/20 0.58
▸ TUBB3 Q13509 3/20 0.58
▸ TUBB2A Q13885 3/20 0.58
▸ TUBB8 Q3ZCM7 3/20 0.58
▸ TUBA3E Q6PEY2 3/20 0.58
▸ TUBA1A Q71U36 3/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17236926 1.00 POLB (0.75) POLBGAAMEN1KMT2ALMNA
SCHEMBL17237196 0.93 MAPT (0.69) POLBGAAMEN1KMT2ALMNA
SCHEMBL17237200 0.93 MAPT (0.69) POLBGAAMEN1KMT2ALMNA
SCHEMBL17236848 0.92 POLB (0.63) POLBGAAMEN1KMT2ALMNA
SCHEMBL17236851 0.92 POLB (0.63) POLBGAAMEN1KMT2ALMNA
SCHEMBL17236975 0.92 POLB (0.63) POLBGAAMEN1KMT2ALMNA
SCHEMBL17236972 0.92 POLB (0.63) POLBGAAMEN1KMT2ALMNA
SCHEMBL17237331 0.91 POLB (0.76) POLBGAAMEN1KMT2ALMNA
SCHEMBL17236831 0.91 POLB (0.62) POLBGAAMEN1KMT2ALMNA
SCHEMBL20007058 0.91 CA1 (0.70) POLBGAAMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2942345-B1 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES FOR THE TREATMENT OF CANCER COUNCIL SCIENT IND RES (IN) 2018-03-28 — — EP claimed
US-9487482-B2 3,4,5-trimethoxystyrylarylaminopropenones as potential anticancer agents COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2016-11-08 — — US claimed
US-20150322009-A1 NOVEL 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES AS POTENTIAL ANTICANCER AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-11-12 — — US claimed
EP-2942345-A1 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES for the treatment of cancer Council of Scientific and Industrial Research (IN) 2015-11-11 — — EP claimed
EP-2942345-B1 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES FOR THE TREATMENT OF CANCER COUNCIL SCIENT IND RES (IN) 2018-03-28 — — EP disclosed
US-9487482-B2 3,4,5-trimethoxystyrylarylaminopropenones as potential anticancer agents COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2016-11-08 — — US disclosed
US-20150322009-A1 NOVEL 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES AS POTENTIAL ANTICANCER AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-11-12 — — US disclosed
EP-2942345-A1 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES for the treatment of cancer Council of Scientific and Industrial Research (IN) 2015-11-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322009-A1 NOVEL 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES AS POTENTIAL ANTICANCER AGENTS MCL1, HCCS, CASP3 POLB 3581/4885GAA 3099/4885MEN1 692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback